Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial
Go back to Cytokinetics aficamten meets dual endpoints in non-obstructive HCM trial| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 75.57 +2.85 (3.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.72 | 52 Week High | $13.18 | |||
| Open | $72.39 | 52 Week Low | $6.00 | |||
| Day High | $76.81 | P/E | N/A | |||
| Day Low | $72.39 | EPS | $-1.24 | |||
| Volume | 872,536 | |||||
